Navigation Links
Pharma R&D Model Needs Academic Tech Transfer Collaboration for the Future of Drug Innovation Says New Report
Date:5/10/2013

DALLAS, May 10, 2013 /PRNewswire-iReach/ -- A new market research report on early-stage technology transfer collaborations & deals between academia and the pharmaceutical industry says a growing emphasis on academic and non-profit organization partnerships could rescue the pharmaceutical industry from the redundancy of an inefficient R&D model and plug the so-called "innovation gap". The report "PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry" argues that collaboration in drug development benefit's both parties, with academia constantly looking for sources of research funding – particularly as governments cut the amount of aid dedicated to federally-funded research – while the pharmaceutical industry would gain a partner to share in the high risks and substantial costs of bringing new medicines to market.

(Logo: http://photos.prnewswire.com/prnh/20130510/CG11593)

"The current R&D paradigm is bloated, duplicative, expensive, and in the long run, untenable," says GlobalData's Healthcare Industry Dynamics Team Analyst, Adam Dion . "There is a growing consensus in the industry that these challenges must be met collectively by bringing together public, private and government organizations to create multi-lateral collaborations to drive the next wave of scientific discovery." Dion explains that the dearth of innovative drugs on the current pharmaceutical landscape is at least partly the result of wasteful R&D activity. 2012 may have boasted the highest number of FDA drug approvals since 1996, but many of these were for "me-too" drugs or medications aimed at niche therapy areas.

"In the past, the big got bigger, as large pharmaceutical companies like Pfizer, Merck, GSK and AstraZeneca relied on organic growth, getting fat and happy on the success of their respective blockbuster drugs," says Dion. "However, many of the same companies did not put in place strategies to drive innovation into the future or manage the consequences of the patent cliff. Many industry participants are now considering a move from an old and inflexible R&D paradigm to a more collaborative and open ecosystem that fosters creativity and information sharing – a substantial cultural shift for an industry with a high level of reluctance to share anything."

Greater co-operation between rival drug companies and non-profit organisations may be a difficult pill for Big Pharma to swallow, states the analyst, but this approach may ultimately prove advantageous in the long-run. This report examines the terms, platform technologies, and deal rationale of 25 pharma-academic alliances from 2012–2013.

Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=91739.

Key Findings of this report include:

  • With the patent cliff and high R&D costs eroding corporate profitability, pharmaceutical companies will look for ways to replenish their pipelines by reaching out to academia in search of novel drug platforms
  • Despite the FDA approving 39 new drugs in 2012, the innovation gap continues, as many of these medicines are 'me-too' drugs, or orphan drugs indicated to treat small segments of the population suffering from rare diseases
  • Difficulty accessing capital and the continued economic recession have led to a deal adverse environment resulting in deals to decline on a global basis
  • Oncology, CNS, immunology and infectious diseases still remain hot therapeutic areas to strike licensing deals with academia

The report "PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry" helps you answer questions like:

  • What are the reasons for increased activity in strategic deals with academia by leading pharmaceutical companies and promising biotechs?
  • What are the deal terms of these collaboration agreements?
  • What therapeutic areas and geographic markets are pharmaceutical companies targeting to partner with academic research institutions?
  • What proprietary platforms and enabling technologies are these pharmaceutical companies trying to access?

Scope of the report covers:

  • Full examination of 25 significant technology transfer deals from 2012 and 2013 involving large pharmaceutical companies and academic organizations including licensing structure and terms
  • Analysis of the key drivers, trends, and strategies behind the deals undertaken by these pharmaceutical companies across major therapeutic areas
  • Discussion of the unsustainability of the current drug research model and how Big Pharma's embrace of collaboration and an open ecosystem could drive the next wave of scientific discovery
  • Tech Transfer in Action : Each section of the report includes a number of case studies and to highlight major themes within technology transfer
  • Platform assessment on enabling drug technologies being employed by academic research institutions of interest to pharmaceutical companies
  • Breakdown of disruptive innovation trends, including open-source patient data, pre-competitive information sharing, 'Big Data' and drug recycling/repurposing approaches

Comprehensive Table of Contents and more @ http://www.rnrmarketresearch.com/pharmasphere-early-stage-technology-transfer-collaborations-enabling-platform-technologies-deal-synergies-between-academia-and-the-pharmaceutical-industry-market-report.html.

About Us:

RnRMarketResearch.com (http://www.rnrmarketresearch.com/) is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Explore our blog @ http://www.rnrmarketresearch.com/blog/. We also have business intelligence and competitive analysis studies focused on multiple industries available @ http://www.sandlerresearch.org/.

Media Contact:

Priyank Tiwari RnR Market Research, +1 888 391 5441, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE RnRMarketResearch.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):